FINWIRES · TerminalLIVE
FINWIRES

Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints

-- Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.

The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.

The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.

An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.

Related Articles

Asia

Light & Wonder's Q1 Results Expected to Be Soft, 2026 Outlook Expected to Be Maintained, Jarden Says

Light & Wonder's (ASX:LNW) first-quarter results are expected to be soft, though the full-year outlook is expected to be maintained, Jarden said in a Tuesday note.Jarden said its first-quarter adjusted earnings before interests, taxes, depreciation, and amortization (AEBITDA) estimate of $326 million is expected to be 5% below consensus. The first quarter represents just 21% of the full-year AEBITDA estimate and proportional contribution set to build through the year.It noted that the underlying demand backdrop remains intact.The investment firm retained its buy rating on Light and Wonder and cut the price target to AU$190 per share from AU$199 per share.

$ASX:LNW
Asia

CECEP Wind-power 2025 Profit Falls 48%; Shares Down 3%

CECEP Wind-power (SHA:601016) posted 2025 attributable net profit of 685.7 million yuan, down 48% from 1.33 billion yuan the previous year.Earnings per share slid to 0.106 yuan from 0.199 yuan, according to a Wednesday filing with the Shanghai bourse.Operating revenue declined 11% year over year to 4.50 billion yuan from 5.03 billion yuan.Shares of the renewable energy company were down 3% in recent trade.

$SHA:601016
Asia

Market Chatter: Indonesia to Grant China Authorization for Reciprocal Bond Issuances

Indonesia's Finance Minister Purbaya Yudhi Sadewa has stated that the country will permit China to issue sovereign bonds in its domestic market, Jakarta Globe reported Tuesday.Indonesia is also planning debt instrument issuances in China after talks on reciprocal cross-border issuances at the spring meetings of the World Bank and International Monetary Fund in the US last week, the report said.China's competitive interest rates have previously prompted Indonesia to reveal plans to issue Panda bonds in the country.Access to more affordable funding options has boosted Indonesia's bargaining leverage with international investors, according to the report.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^JKSE